Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17–36

The currently available nonavalent human papillomavirus (HPV) vaccine exploits the highly antigenic L1 major capsid protein to promote high-titer neutralizing antibodies, but is limited to the HPV types included in the vaccine since the responses are highly type-specific. The limited cross-protectio...

Descripción completa

Detalles Bibliográficos
Autores principales: Bywaters, Stephanie M., Brendle, Sarah A., Tossi, Kerstin P., Biryukov, Jennifer, Meyers, Craig, Christensen, Neil D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707543/
https://www.ncbi.nlm.nih.gov/pubmed/29125554
http://dx.doi.org/10.3390/v9110336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707543/
https://www.ncbi.nlm.nih.gov/pubmed/29125554
http://dx.doi.org/10.3390/v9110336

Ejemplares similares